Brandon Capital Partners
43
20M
31
2.39
5
0.28
3
- Stages of investment
- Areas of investment
Summary
In 2006 was created Brandon Capital Partners, which is appeared as VC. The leading representative office of defined VC is situated in the Melbourne. The company was established in Australia.
The top amount of exits for fund were in 2018. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. Comparing to the other companies, this Brandon Capital Partners performs on 17 percentage points less the average number of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.
Besides them, we counted 6 critical employees of this fund in our database.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Brandon Capital Partners, startups are often financed by Split Rock Partners, Delphi Ventures, Uniseed Ventures. The meaningful sponsors for the fund in investment in the same round are Uniseed Ventures, GBS Ventures, Terra Rossa Capital. In the next rounds fund is usually obtained by Medical Research Commercialisation Fund (MRCF), Kohlberg Kravis Roberts, Uniseed Ventures.
Among the most popular portfolio startups of the fund, we may highlight EBR Systems, Signostics, MecRx. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Australia. We can highlight the next thriving fund investment areas, such as Medical Device, Biotechnology. The fund has exact preference in a number of founders of portfolio startups.
Investments analytics
Analytics
- Total investments
- 43
- Lead investments
- 5
- Exits
- 3
- Rounds per year
- 2.39
- Follow on index
- 0.28
- Investments by industry
- Biotechnology (30)
- Medical (26)
- Health Care (25)
- Medical Device (14)
- Therapeutics (12) Show 11 more
- Investments by region
-
- United States (9)
- United Kingdom (7)
- Australia (25)
- Germany (1)
- Peak activity year
- 2022
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 9
- Avg. valuation at time of investment
- 11M
- Group Appearance index
- 0.88
- Avg. company exit year
- 11
- Avg. multiplicator
- 4.76
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Elastagen | 07 Jan 2016 | Medical Device, Medical, Clinical Trials | Early Stage Venture | 9M | New South Wales, Sydney, Australia |
| ExSafe | 01 Apr 2008 | Software, Mobile, Security, Cloud Computing | Seed | 1M | Dublin, Dublin, Ireland |
| Pheon Therapeutics | 21 May 2024 | Biotechnology, Medical, Life Science, Therapeutics | Early Stage Venture | 120M | England, London, United Kingdom |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.